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ARTICLE
Co-expression of CD39 and CD103 identifies
tumor-reactive CD8 T cells in human solid tumors
Thomas Duhen1, Rebekka Duhen2, Ryan Montler1, Jake Moses1, Tarsem Moudgil2, Noel F. de Miranda3,
Cheri P. Goodall2, Tiffany C. Blair1, Bernard A. Fox2, Jason E. McDermott 4, Shu-Ching Chang5,
Gary Grunkemeier5, Rom Leidner2, Richard Bryan Bell2 & Andrew D. Weinberg1,2
Identifying tumor antigen-specific T cells from cancer patients has important implications for
immunotherapy diagnostics and therapeutics. Here, we show that CD103+CD39+ tumor-
infiltrating CD8 T cells (CD8 TIL) are enriched for tumor-reactive cells both in primary and
metastatic tumors. This CD8 TIL subset is found across six different malignancies and dis-
plays an exhausted tissue-resident memory phenotype. CD103+CD39+ CD8 TILs have a
distinct T-cell receptor (TCR) repertoire, with T-cell clones expanded in the tumor but
present at low frequencies in the periphery. CD103+CD39+ CD8 TILs also efficiently kill
autologous tumor cells in a MHC-class I-dependent manner. Finally, higher frequencies of
CD103+CD39+ CD8 TILs in patients with head and neck cancer are associated with better
overall survival. Our data thus describe an approach for detecting tumor-reactive CD8 TILs
that will help define mechanisms of existing immunotherapy treatments, and may lead to
future adoptive T-cell cancer therapies.
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The immune system can recognize and destroy tumor cellsthrough T-cell-mediated mechanisms. Hence, a variety oftherapeutic approaches have focused on boosting and/or
restoring T-cell function in cancer patients1,2. An effective
immune response involves the concerted action of several dif-
ferent cell types among which CD8 T cells are key players that
can specifically recognize and kill cancer cells via the release of
cytotoxic molecules and cytokines3. A percentage of tumor-
infiltrating CD8 T cells (CD8 TIL) recognize tumor-associated
antigens, which include overexpressed self-antigens, as well as
tumor-specific neoantigens, which arise as a consequence of
tumor-specific mutations4. According to the current paradigm,
tumor-specific CD8 T cells are primed in tumor-draining lymph
nodes (LN) and then migrate via the blood to the tumor, where
they exert their effector function. Previous work has shown that
CD8 TILs represent a heterogeneous cell population comprising
tumor-specific T cells as well as bystander T cells. Both tumor-
specific and bystander T cells are recruited to the tumor site by
the inflammation associated with tumor progression. However, it
has proved difficult to easily identify cancer antigen-specific CD8
TILs within human tumors5–8.
Recruitment and retention within the tumor requires T cells to
express a defined set of chemokine receptors and integrins.
Among the integrins, integrin αE, also known as CD103, is
expressed on a subset of dendritic cells in the gut and a popu-
lation of T cells found among peripheral tissues, known as tissue-
resident memory T cells (TRM)9–11. Several groups have shown
that CD103 is also expressed on a subset of CD8 TILs in multiple
solid human tumors12–17 and it is known that TGF-β upregulates
its expression18.
More recently, the expression and function of CD39 and CD73
in human solid tumors has been of interest19, especially with
regard to treatments aimed at blocking their function20. CD39 is
an ectonucleotidase expressed by B cells, innate cells, regulatory
T cells as well as activated CD4 and CD8 T cells, which, in
coordination with CD73 can result in local production of ade-
nosine leading to an immunosuppressive environment. Further-
more, CD39 was identified as a marker for exhausted T cells in
patients with chronic viral infections21.
In this manuscript, we show that co-expression of CD39 and
CD103 identifies a unique population of CD8 TILs found only
within the tumor microenvironment. These cells, which have a
TRM phenotype and express high levels of exhaustion markers,
have a high frequency of tumor-reactive cells, have a distinct TCR
repertoire and are capable of recognizing and killing autologous
tumor cells. Finally, there is a greater overall survival (OS) in head
and neck cancer patients that have a higher frequency of CD103
+CD39+ CD8 TILs at time of surgery. These data provide an
approach to identify tumor-reactive CD8 T cells and will have
important ramifications for developing future therapeutic
strategies.
Results
CD103 and CD39 identify tumor-resident CD8 T cells. Recent
work has shown that tumor-reactive CD8 T cells can be found
within the CD103+ subset of TILs from patients with high-grade
serous ovarian cancer (HGSC) and non-small cell lung cancer
(NSCLC)12,15. However, repeated exposure to their cognate
antigen can induce an exhausted state, ultimately impairing their
capacity to control tumor growth22–24. Our preliminary data
revealed that one of the top differentially expressed genes between
CD103+ and CD103− CD8 TILs was ENTPD1, which encodes for
the protein CD39 (data not shown), a marker for exhausted CD8
T cells in patients with chronic viral infections21. To further
explore the CD103+ CD8 TIL subset, we examined the expression
of CD39, PD-1, CD127, and additional cell surface markers
associated with activation/exhaustion in a patient with head and
neck squamous cell carcinoma (HNSCC). Interestingly, CD103+
CD8 TILs expressed high levels of CD39, PD-1, and CD69 with a
large fraction of cells co-expressing all three markers (Fig. 1a, b).
CD39+PD-1+CD69+CD103+ CD8 TILs also expressed very low
levels of CD127, thus displaying a chronic activation phenotype.
Flow cytometric analyses of CD103 and CD39 on CD8 TILs
revealed three main cell populations, which included CD103-
CD39− double-negative (DN) T cells, CD103+CD39− single-
positive (SP) T cells and CD103+CD39+ double-positive (DP)
T cells, and a rare CD103−CD39+ T-cell population (SP39)
(Supplementary Fig. 1a, b). DP CD8 TILs were detected at rela-
tively high frequencies in tumor specimens obtained from
patients with melanoma, lung cancer, HNSCC, ovarian cancer,
and rectal cancer (Fig. 1c, d and Supplementary Fig. 2a). The
percentage of DP CD8 TILs was lower in a subset of HNSCC
patients as well as in most patients with microsatellite stable
(MSS) colon cancer and colorectal liver metastasis (CRLM)
(Fig. 1c, d). Interestingly, CD8 TILs from patients with DNA
mismatch repair-deficient or microsatellite instability-high
(MSIhigh) colon cancer had a high frequency of DP CD8 T cells
and this group has been associated with increased responsiveness
to immunotherapy25–28.
We next sought to determine whether the DP CD8 TILs could
be found at primary and metastatic tumor sites in several HNSCC
patients. Figure 1e shows results from a representative patient
where DP CD8 T cells were found in both the primary tumor and
metastatic LN; however, DP CD8 T cells were absent or present at
very low frequency in the peripheral blood and an uninvolved
LN. A similar distribution profile was found in most HNSCC
patients analyzed (Fig. 1f). Collectively, these results indicate that
CD39 expression on CD103+ CD8 T cells identifies a population
of cells found predominantly in the tumor microenvironment.
DP CD8 TILs are exhausted and display a TRM gene signature.
To gain a more in depth understanding of the CD8 TIL biology,
the DN, SP, and DP CD8 T-cell subsets were sorted from the
tumor and gene-expression profiles were assessed by microarray
from three HNSCC and two ovarian tumors (Supplementary
Fig. 2c). Volcano plot messenger RNA (mRNA) comparisons
between the DP and DN CD8 T cells identified 219 transcripts
that were differentially expressed between these two cell popu-
lations (Fig. 2a). Principal component analysis (PCA) and
unsupervised hierarchical clustering revealed that the gene sig-
nature for DP and DN CD8 T cells were distinct, whereas the SP
CD8 T cells displayed an intermediate gene signature, and those
signatures segregated by CD8 T-cell subset rather than by patient
or tumor type (Fig. 2b, c and Supplementary Table 1). Gene-set-
enrichment analysis (GSEA) also revealed that gene transcripts
associated with T-cell exhaustion such as PDCD1 (PD-1), CTL4
(CTLA-4), HAVCR2 (TIM-3) were significantly enriched in DP
CD8 as compared to DN CD8 and SP CD8 TILs while CD28
expression was decreased (Fig. 2d, e and Supplementary Fig. 3).
In contrast, DP CD8 TILs demonstrated lower expression of
genes involved in T-cell recirculation, such as KLF2, SELL
(CD62L), S1PR1, and as a result, showed a significant enrichment
in the TRM gene signature when compared to DN CD8 and SP
CD8 TILs (Fig. 2d, e and Supplementary Fig. 3).
To confirm the gene array results, we analyzed protein expression
of several differentiation and activation markers by flow cytometry
(Fig. 3a, b and Supplementary Fig. 2a). The DP CD8 TILs expressed
higher levels of CD69 when compared to SP or DN CD8 TILs.
CD69 is an activation molecule that is upregulated after T-cell
stimulation and antagonizes sphingosine 1-phosphate receptor 1
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Fig. 1 Tumor-infiltrating CD103+ CD8 T cells coexpress the ectonucleotidase CD39. a Representative gating strategy for the flow cytometric analysis of
tumor-infiltrating CD8 T cells (CD8 TIL) for a HNSCC patient. Numbers in plots indicate the percent cells in respective gates. b viSNE analysis of CD103+
CD8 TILs as shown in a. The gate identifies the CD103+ CD8 T cells with the highest expression of CD39. The gate is applied to all plots showing
expression levels of PD-1, CD69, and CD127. c Flow cytometric analysis of CD8 TIL isolated from representative HNSCC, melanoma, ovarian cancer, and
CRLM patients. Numbers in each quadrant indicate percent cells positive for CD39 and/or CD103 on CD3+CD8+ T cells. d Summary of the frequency of
CD39+CD103+ (DP) CD8 TILs among patients with different solid malignancies. Shown are 65 HNSCC, 5 lung cancers, 8 melanomas, 4 ovarian cancers, 5
rectal cancers, 5 MSS colon cancers, 8 MSIhigh colon cancers, and 10 CRLM. e Flow cytometric analysis of the percentage of DP CD8 T cells in peripheral
blood, uninvolved LN, primary tumor, and metastatic LN from a representative HNSCC patient. Numbers in each quadrant indicate percent cells positive for
CD39 and/or CD103 on CD3+CD8+ T cells. Data are representative of 41 HNSCC patients analyzed (7 patients for uninvolved LN and 9 patients for Met
LN). Percentages are summarized in f. Small horizontal lines indicate mean ± SEM
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Fig. 2 Gene-expression analysis of DP CD8 TILs reveals an exhausted profile and a gene signature reminiscent of TRM cells. a Volcano plot showing
differential gene expression of the DP vs. DN CD8 T-cell subsets (log2-transformed). The dashed line delineates the differentially expressed genes (red
dots) when using a false-discovery rate (FDR) <5%. b PCA of the 219 differentially expressed genes between the DP and DN CD8 TILs with a FDR <5%
among all three subsets. Dots indicate samples of the three different populations from a total of five patients. PCA 1 and 2 represents the largest source of
variation, combined accounting for 51%. Each symbol represents one patient. c Unsupervised clustering of the 219 differentially expressed genes between
DP and DN CD8 on all three subsets of CD8 TIL from five patients. Blue color indicates downregulated genes, orange indicates upregulated genes. d GSEA
of “T-cell exhaustion” and “TRM” gene sets in the transcriptome of DP CD8 vs. that of DN CD8 TILs, presented as the normalized enrichment score (NES).
e Examples of differentially expressed genes between DP CD8 and DN CD8 TILs present in the “TRM” (blue) or the “T-cell exhaustion” (orange) gene sets.
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CD127, and CD28, delineating a TRM phenotype, on the three CD8 TIL subsets (top, one representative patient shown, colors match key). Summary of the
frequency/expression level of the above-mentioned markers among several cancer patients (n= 12 for CD69; n= 10 for CCR7; n= 13 for CD127; and n= 6
for CD28, bottom). Each dot represents one patient. b Ex vivo phenotypic analysis of the expression of surface and intracellular proteins PD-1, CTLA-4,
TIM-3, 4-1BB, and Ki-67, delineating an activated/chronically stimulated phenotype, on the three CD8 TIL subsets (top, one representative patient shown,
colors match key). Summary of the frequency of the above-mentioned markers among several cancer patients (n= 11 for PD-1; n= 5 for CTLA-4; n= 8 for
TIM-3; n= 8 for 4-1BB; and n= 17 for Ki-67, bottom). Each dot represents one patient. c Representative flow cytometric analysis of IFN-γ and TNF-α
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(S1PR1)-mediated egress of T cells from tissue, thereby playing a
role in tissue retention29. The DP CD8 TILs also exhibited lower
expression of CCR7, CD127, and CD28, indicative of an effector
memory phenotype30. Interestingly, while a fraction of all CD8 TIL
sub-populations expressed PD-1 (Supplementary Fig. 4), the level of
PD-1 expression was highest on the DP CD8 TILs. In addition,
CTLA-4 and TIM-3 were almost exclusively expressed within the
DP CD8 T-cell population. The DP CD8 TILs also displayed
increased frequencies of cells expressing 4-1BB and Ki-67,
suggesting that these cells had recently encountered their cognate
antigen and were proliferating in the tumor.
Effector function of the DN, SP and DP CD8 T cells was
assessed by analyzing cytokine production and granzyme B
expression. We found that fewer DP CD8 TILs produced
interferon (IFN)-γ and/or tumor necrosis factor (TNF)-α than
did the DN and SP CD8 TILs after Phorbol 12-Myristate 13-
Acetate (PMA)/ionomycin treatment (Fig. 3c, d). Interestingly,
the DP CD8 TILs had an increased cytotoxic potential as
demonstrated by a significantly higher frequency of granzyme B-
positive cells (Fig. 3e).
TGF-β and TCR stimulation upregulate CD39 and CD103.
Given that DP CD8 T cells were found only at sites where tumor
cells were present, we wanted to explore the mechanism for CD39
and CD103 upregulation. It is well established that TGF-β drives
expression of CD103 on T cells18. TGF-β is often produced
within the tumor microenvironment and may play a major role in
cancer progression in part by suppressing T-cell immunity31,32.
CD39 expression is found on exhausted CD8 T cells in mice
and humans21,33, suggesting that chronic TCR stimulation may
upregulate CD39. Therefore, we analyzed the kinetics of CD103
and CD39 upregulation on naive CD8 T cells from several healthy
donors stimulated via the TCR in the presence or absence of
TGF-β (Fig. 4 and Supplementary Fig. 5). TGF-β greatly
increased CD103 expression 3 days following TCR stimulation
(75 ± 16.8%). CD39 expression, which was detected 3 days after
TCR activation, peaked at day 9. Maximum CD39 expression
required prolonged TCR stimulation as it was only partially
upregulated when the TCR stimulation was removed after 24 h.
The lack of CD39 upregulation was not due to sub-optimal TCR
stimulation as the expression of other activation markers such as
PD-1 was induced on T cells stimulated for only 24 h (Fig. 4).
Taken together, these data show that prolonged TCR stimulation
in the presence of TGF-β is necessary for the maximum co-
expression of CD103 and CD39 on CD8 T cells.
TCR repertoire analysis suggests clonal expansion of DP CD8.
Thus far, our data suggest that DP CD8 TILs may be enriched for
cells recognizing cognate antigens within the tumor. If this
assumption is correct, we might observe selective expansion of
dominant TCR clonotypes within the DP CD8 TILs. Sequencing
of the CDR3 region of the TRB genes revealed that DP CD8
TILs were indeed more oligoclonal compared to memory CD8
T cells in the peripheral blood and to DN and SP CD8 TILs
(Fig. 5a). The 30 most frequent clonotypes were evaluated in a
Human Papillomavirus (HPV)-positive HNSCC, a HPV-negative
HNSCC, an ovarian tumor, and a melanoma tumor, and they
accounted for 56, 62, 66 and 86%, respectively of the DP CD8
TILs; however, the top 30 clonotypes within the DN CD8 TILs
only represented 26, 23, 38, and 35% in the same patients. The 30
most frequent clonotypes in the DP CD8 TILs were far less fre-
quent in the DN or the SP CD8 TILs, and represented <2.5% of
the DN CD8 TIL repertoire within these four patients (Supple-
mentary Fig. 6a). Consequently, very few TCR clonotypes were
shared between the DP CD8 TILs and the other CD8 TIL subsets
(Fig. 5b). In contrast, a greater number of TCR clonotypes were
shared between DN CD8 TILs and SP CD8 TILs. The majority of
TCR clonotypes present in DN CD8 TILs were also shared with
memory CD8 T cells within an uninvolved LN and in peripheral
blood (R2= 0.7710 and 0.2022, respectively) (Fig. 5c). These data
suggest that the DN CD8 TILs can exit the tissue into the per-
iphery as would be predicted by the lack of a resident memory
signature (Fig. 2d). In contrast, the clonotypes present within the
DP CD8 TIL repertoire were detected at very low frequency in the
aforementioned peripheral tissues (R2= 0.0026 and R2= 0.0038,
respectively) (Fig. 5c), suggesting that these cells were pre-
ferentially retained within the tumor. Calculation of the Morisita
index, an abundance-based similarity index that determines the
overlap between two populations, further supports these results
showing consistent findings across six patient samples (Fig. 5d).
Similar results were also obtained when calculating the Jaccard
index with these samples (Supplementary Fig. 6b). Of note, we
also observed a strong overlap of the DP CD8 TIL repertoire
between the primary tumor and metastatic LNs in two HNSCC
patient samples (Supplementary Fig. 6c). Collectively, these
results support antigen-driven stimulation of the DP CD8 T cells
at the tumor site, which results in local activation and expansion
of these cells.
DP CD8 TILs recognize and kill tumor cells. To determine
whether the DP CD8 TILs were enriched for cells that recognize
and kill autologous tumor cells, we used tumor cell lines gener-
ated from four melanoma patients and two HNSCC patients in T
cell/tumor co-culture experiments. CD8 T cells were sorted from
tumor digests based on the expression of CD103 and CD39 and
expanded in vitro (Supplementary Fig. 2c). Following expansion,
the DN, SP, and DP CD8 TILs were screened for reactivity to
autologous tumor cell lines by measuring upregulation of the
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activation marker 4-1BB and IFN-γ secretion. In all six patients,
the DP CD8 TILs exhibited greater tumor reactivity when com-
pared to the DN or SP CD8 TILs (Fig. 6a and Supplementary
Fig. 7a). The frequency of tumor-reactive CD8 TILs within the
DP population was 87% at the highest tumor-to-T-cell ratio for
patient 1, and a mean of 51% tumor-reactive cells was found over
the six patient samples analyzed (ranging from 13.2 to 87.9%).
The DP CD8 TILs specifically recognized autologous tumor cells
in an major histocompatibility complex (MHC)-class I-
dependent manner, as little to no reactivity was observed fol-
lowing Major Histocompatibility Complex (MHC)-class I
blockade or when T cells were co-cultured with an allogeneic
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tumor cell line (Fig. 6b and Supplementary Fig. 7b). The sorted
DP CD8 TILs were not enriched for viral-specific CD8 T cells as
measured by IFN-γ secretion after incubation with a peptide pool
derived from Epstein-Barr virus (EBV), Cytomegalovirus (CMV)
and influenza virus (Fig. 6c and Supplementary Fig. 8) (no viral
reactivity was detected in patient 4). To address whether the
tumor-reactive DP CD8 TILs could directly kill autologous tumor
cells, we co-cultured the expanded T-cell subsets with autologous
tumor cell lines and monitored tumor killing. In accord with 4-
1BB upregulation, the DP CD8 T cells were able to kill autologous
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tumor cells in an MHC-class I-dependent manner as illustrated
by the increasing number of caspase 3/7+ events (Fig. 6d, e). In
contrast, little to no tumor cell killing was observed in the DN or
SP CD8 TIL populations (Fig. 6d, e). Taken together, our data
show that CD39 and CD103 co-expression strongly enriches for
CD8 T cells that recognize and kill tumor cells.
Frequency of DP CD8 in tumors correlates with increased OS.
Since the DP CD8 TILs were enriched for tumor-reactive T cells,
we explored the possible relationship between the frequency of
DP CD8 TILs and OS in a small cohort of HNSCC patients (n=
62). Following surgery, the frequency of DP CD8 T cells among
total CD8 TILs was determined within primary tumors by flow
cytometry and patients then received standard of care treatment
(s). Patients were segregated based on the mean frequency of the
DP CD8 T cells within this cohort and their characteristics are
detailed in Supplementary Table 2. Our analysis revealed that
there was a significant difference in stage between DP-low and
DP-high groups. Patients with lower frequency of DP CD8 T cells
were more likely to have a higher pathologic stage (86% vs. 58%,
p-value= 0.02), but there were no significant differences with
respect to the other characteristics tested. Univariate survival
analysis using log-rank test showed that patients whose tumors
had a higher percentage of DP CD8 TILs at the time of surgery
correlated with better OS (3-year survival: 89% vs. 56%; p-value
= 0.0191) (Fig. 7a and Supplementary Table 5). This association
was more significant in the HPV-negative subgroup (3-year
survival: 86% vs. 26%; p-value= 0.0119) (Fig. 7b and Supple-
mentary Table 6). In contrast, an increase in the frequency of SP
CD8 TILs did not correlate with increased OS (Fig. 7c, d). There
was no significant association between stage and OS (Supple-
mentary table 3), probably due to small sample size and small
number of events. To account for confounding variables when
evaluating the association of DP CD8 TILs with OS, we took HPV
status as well as stage, age, gender, and smoking status into
consideration in the multivariable analysis, though they did not
show significant association with survival in univariate analysis.
The results showed that, after controlling for those variables,
higher percentage of DP CD8 TILs at the time of surgery was
associated with better OS (hazard ratio (HR)= 0.23; 95% CI=
0.04–0.96; p-value= 0.04; Supplementary Table 3), and this
association remained more significant in the HPV-negative sub-
group (HR= 0.07; 95% CI= 0.003–0.54; p-value= 0.01; Supple-
mentary Table 4). Specifically, taking DP CD8 as a continuous
variable with log(2) transformed (i.e., log(DP CD8, 2)) in the
HPV-negative subgroup showed that controlling for the same
variables, the hazard of death significantly decreased 45% with
two-fold increase of DP CD8 (HR (95% CI)= 0.55 (0.32, 0.95), p-
value= 0.03). To confirm our data, we interrogated the TCGA
data sets for HNSCC, lung adenocarcinoma, and lung squamous
cell carcinoma, comparing patients with high expression of
ENTPD1 (CD39) and ITGAE (CD103) transcripts to patients
with lower expression of those genes. Using this approach, we
showed that patients in the CD39hiCD103hi group demonstrated
a better OS at 3 years than patients from the CD39loCD103lo
group for all three cancer types (Supplementary Fig. 9). Impor-
tantly, using both genes for the analysis was consistently better at
predicting survival than CD103 alone.
Collectively, we show that the frequency of DP CD8 T cells in
primary tumors correlates with increased OS in a cohort of
HNSCC patients and within the TCGA data sets for HNSCC and
lung cancer patients.
Discussion
In this study, we show that within the CD8 TILs, the
CD103+CD39+ cells are enriched for tumor-reactive T cells in
human solid tumors. These cells have an exhausted TRM phe-
notype, a TCR repertoire that is distinct from other CD8 TIL
subsets, and can kill autologous tumor cells in a MHC-restricted
manner. Importantly, we found that increased frequencies of the
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DP CD8 TILs correlate with a significantly reduced risk of death
for patients with HPV-negative HNSCC, suggesting an important
role for tumor antigen-specific CD8 TILs in limiting tumor
growth in these patients.
It has previously been suggested by several groups that
CD103+ CD8 TILs contained tumor-reactive CD8 T cells in
HGSC and NSCLC12,15. Moreover, similarly to our work, the
study by Ganesan et al.34 recently showed that CD103+ CD8 TILs
displayed a TRM gene signature and were highly activated, sup-
porting a common gene signature for CD103+ CD8 TILs in
multiple solid tumors. However, our study shows that gating on
the CD39+ cells within the CD103+ CD8 TILs population is
essential to enrich for tumor-reactive CD8 T cells, as the SP CD8
TILs showed little reactivity to autologous tumor cells (Fig. 6a and
Supplementary Fig. 7a). In addition, the analysis of the TCR
repertoire and gene signatures further indicated that this subset is
a unique CD8 TIL sub-population.
The DP CD8 TILs were present at high frequencies within
primary tumors and tumor-infiltrating LNs; however, there was
little to no expression of these two markers on peripheral CD8
T cells (blood or uninvolved LN; Fig. 1e, f) within tumor-bearing
hosts. Several different tumor types were assessed and the highest
percentage of DP CD8 TILs were found in melanoma and MSI-
high colon cancer, both tumors with high mutational burden that
show the highest response rates to immunotherapy26,27, while
intermediate percentages were found in HNSCC, lung, and
ovarian cancer patients (all known to respond to PD-1 blockade
but to a lesser extent than melanoma and MSIhigh colon cancer)
(Fig. 1d). Strikingly, we found fewer DP CD8 TILs in primary
MSS colon cancer and CRLM, and these patients tend not to
respond well to immunotherapy. Our data suggest that MSS
colon cancer patients have a lower frequency of tumor-reactive
TILs compared to other malignancies; however, being able to
identify the tumor-reactive TILs in these patients may allow for
their expansion and future immunotherapy treatment options.
Recent advances in cancer immunotherapy treatment have
shown that adoptive T-cell therapy was effective in some tumor
types, particularly in stage IV melanoma patients1,35–38. However,
efficacy of this treatment strategy is tightly linked to the identi-
fication and in vitro expansion of tumor-reactive T cells. Cur-
rently, PD-1 is a marker used to identify antigen-reactive T cells
among TILs and/or peripheral blood5,39–41. Here we show that
PD-1+ cells were detected in all CD8 TIL sub-populations
(Supplementary Fig. 4); however, only the DP CD8 TIL subset
was enriched for tumor recognition and immune specific tumor
killing (Fig. 6a, d). Therefore, using CD39 and CD103 to enrich
for tumor-reactive CD8 T cells prior to TIL expansion may be a
way to increase the clinical success of adoptive immunotherapy.
Also, identifying TCR sequences within the DP CD8 TILs that
specifically recognize tumor antigens may aid in TCR engineering
approaches that would lead to personalized tumor therapies in
patients that have failed approved treatments.
The activated phenotype of the DP CD8 TILs and their skewed
TCR repertoire strongly suggest that these cells are recognizing
their cognate antigen within the tumor microenvironment.
However, in this study, the CD8 TILs were isolated from pro-
gressively growing tumors, highlighting the fact that tumors can
develop immune escape mechanisms that ultimately prevent the
tumor-reactive CD8 TILs from controlling tumor growth. A
potential explanation is chronic TCR stimulation within the
tumor resulting in increased expression of activation/exhaustion
markers, some of which participate in the downregulation of
immune function (e.g., PD-1, CTLA-4 and TIM-3). Sustained
expression of these checkpoints molecules can have detrimental
effects on the immune response resulting in tumor outgrowth42.
Therefore, using checkpoint inhibitors could release inhibition on
the tumor-reactive DP CD8 TILs allowing them to fully exert
their effector function. To address this hypothesis, it would be of
interest to examine patients that respond to anti-PD-1 and anti-
CTLA-4 therapies for changes in the frequency and/or activation
status of the DP CD8 TILs. CD39 is another potential immune
inhibitory pathway, which is highly expressed on the DP CD8
TILs. CD39 is an ectonucleotidase that hydrolyzes extracellular
ATP and ADP into AMP, which is then processed into adenosine
by CD73, an ecto-5′-nucleotidase expressed by many tumor cell
types19. Adenosine is a potent immunoregulator and, when
binding to A2A receptors on T lymphocytes, it enhances the
accumulation of intracellular cAMP, thereby dampening T-cell
activation43. Interfering with the adenosine pathway via blockade
of the CD39/CD73 axis or adenosine receptors on T cells within
the tumor microenvironment might be another promising ther-
apeutic strategy to increase the function/potency of the DP CD8
TIL and this pathway is currently being tested in cancer-bearing
hosts20.
Based on the aforementioned expression of inhibitory/check-
point receptors, CD8 T cells have been classified and termed
exhausted, anergic and/or dysfunctional. A recent study has
reported that T-cell dysfunction is epigenetically imprinted and
that two dysfunctional states exist, a “plastic” state from which
T cells can be rescued and a “fixed” state, in which T cells are
resistant to reprogramming44. Based on their data and the ex vivo
phenotype of DP CD8 TILs defined within this manuscript, one
could conclude that the majority of the CD8 TILs are dysfunc-
tional. However, our cohort of HNSCC patients indicates that a
higher frequency of DP CD8 TILs is associated with a lower risk
of death, suggesting that tumor antigen-specific CD8 TILs may
play an active role in the control of tumor growth. Moreover, we
have demonstrated that the DP CD8 TILs can kill autologous
tumor cells efficiently, suggesting that these T cells are able to
regain function after in vitro expansion. Hence, the plasticity and
heterogeneity of the DP CD8 TILs will be explored in future
studies to further elucidate the functional role of these cells in
anti-tumor immunity.
In conclusion, we propose a model where CD8 T cells are
primed by dendritic cells presenting tumor antigens within the
tumor-draining LN, then migrate to the tumor where they
recognize their cognate antigen and clonally expand. The con-
sequence of this recurrent TCR activation in a TGF-β-rich
environment is the upregulation of CD39 and CD103 on CD8
TILs. Activation of these cells also leads to the downregulation of
proteins important for T-cell recirculation resulting in the
retention of DP CD8 TILs within the tumor. Finally, repetitive
TCR stimulation of the DP CD8 TILs leads to impaired effector
function, immune escape, and ultimately tumor progression. We
believe that this work leads to a deeper understanding of human
CD8 TIL biology, and using CD39 and CD103 to identify tumor-
reactive CD8 TILs in solid tumors will lead to important
mechanistic insights when evaluating the efficacy of immu-
notherapeutic treatments.
Methods
Healthy donor and patient samples. Peripheral blood, uninvolved LNs, meta-
static LNs, and tumor samples were obtained from individuals with HNSCC,
melanoma, colon cancer, rectal cancer, lung cancer, CRLM, and ovarian cancer. All
subjects signed written informed consent approved by the Providence Portland
Medical Center Institutional Review Board (IRB protocol no. 06-108A). At the time
of sample collection, patients were not undergoing therapy. Previously, patients
had undergone a wide range of therapies, including chemotherapy, radiotherapy,
surgery and immunotherapy, or none of the above. Peripheral blood mononuclear
cells (PBMCs) were purified from whole blood over Ficoll-Paque PLUS (GE
Healthcare) gradient and cryopreserved prior to analysis. Tumor specimens were
prepared as follows: under sterile conditions, tumors were cut into small pieces and
digested in RPMI-1640 supplemented with hyaluronidase at 0.5 mg/ml, collagenase
at 1 mg/ml (both Sigma-Aldrich), DNase at 30 U/ml (Roche) as well as human
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serum albumin (MP Biomedicals) at 1.5% final concentration. Cells were digested
for 1 h at room temperature under agitation with a magnetic stir bar. Cell sus-
pensions were filtered through a 70 µm filter. Tumor-infiltrating lymphocytes were
enriched as described above by Ficoll-Paque PLUS density centrifugation. Tumor
single-cell suspensions were cryopreserved until further analysis.
Antibodies and flow cytometry. The following fluorescent-labeled antibodies
were used: fluorescein isothiocyanate (FITC), allophycocyanin (APC)-Cy7, and PE/
Dazzle 594 anti-CD3 (UCHT1; 1:50—#300440, 1:100—#300426 and 1:100—
#300450, respectively), BV785 anti-CD4 (OKT-4; 1:100—#317442), BV510 anti-
CD8 (RPA-T8; 1:100—#301048), BV650 anti-CD25 (BC96; 1:100—#302634), PE/
Dazzle 594 anti-CD28 (CD28.2; 1:50—#302941), APC-efluor780 anti-CD45RA
(HI100; 1:100—#47-0458-42), BV605 anti-CD69 (FN50; 1:50—#310938), BV421
anti-CD127 (A019D5; 1:50—#351310), AlexaFluor (AF)-647 anti-PD-1
(EH12.2H7; 1:50—#329910), APC anti-CTLA-4 (BNI3; 1:25—#369611), PE anti-4-
1BB (4B4-1; 1:40—#309804), PE/Dazzle 594 and BV421 anti-CCR7 (G043H7; 1:50
—#353236 and #353208, respectively), AF700 anti-granzyme B (GB11; 1:100—
#560213), BV605 anti-IFN-γ (4S.B3; 1:50—#502536), APC anti-TNF-α (Mab11;
1:200—#17-7349-82) (all from Biolegend); BV421 anti-CD27 (M-T271; 1:50—
#562513), FITC anti-CD127 (HIL-7R-M21; 1:10—#560549), PE-Cy7 anti-PD-1
(EH12.1; 1:50—#561272), AF 488 anti-Ki-67 (B56; 1:100—#561165) (all from BD
Biosciences); PE anti-CD3 (UCHT1; 1:100—#300408), PE anti-CD28 (CD28.2;
1:50—#12-0289-42), APC and PE-Cy7 anti-CD39 (eBioA1; 1:100—#17-0399-42
and #25-0399-42, respectively), PE and PerCP-efluor710 anti-CD103 (B-Ly7 and
Ber-ACT8; 1:100—#12-1038-42 and 1:50—#46-1037-42, respectively) (all from
eBioscience); PE anti-TIM-3 (344823; 1:20—#FAB2365P) (R&D systems). A fixable
live/dead dye was used to distinguish viable cells (Biolegend). Cell surface staining
was performed in FACS buffer (PBS, supplemented with 1% FBS and 0.01% NaN3).
Intracellular staining was performed using the Fix/Perm kit from eBioscience
according to the manufacturer’s instructions. To analyze cytokine production by
PBMCs and TIL ex vivo, cells were stimulated for 5 h with Phorbol 12-Myristate
13-Acetate (PMA) (0.2 µM) and ionomycin (1 µg/ml), with BFA (10 µg/ml) present
for the last 2.5 h. Intracellular cytokine staining was performed using the CytoFix/
CytoPerm kit from BD Biosciences according to the manufacturer’s instructions.
Stained cells were acquired on a LSRII and LSRFortessa flow cytometer, or the
FACS AriaII (all BD Biosciences), for cell sorting. Data were analyzed with FlowJo
software (Treestar).
Cell sorting and T-cell expansion. Cryopreserved PBMC and TIL were thawed
and enriched for T lymphocytes using the T-cell enrichment kit from Stemcell. For
TIL enrichment, EpCAM beads (StemCell) were added to the cocktail. The enri-
ched fractions were then labeled and populations of interest were purified after cell
sorting to 99% purity on a FACSAria II. Briefly, naive CD8 T cells were sorted as
CD8+CD4−CD45RA+CCR7+ cells and memory CD8 T cells were sorted as CD8
+CD4−CD45RA−CCR7+/− (total memory). CD8 subsets from TIL were sorted as
CD3+CD4−CD8+CD45RA−CCR7+/−CD39−CD103− (DN), CD3+CD4−
CD8+CD45RA−CCR7+/−CD39−CD103+ (SP), and CD3+CD4−CD8+CD45RA−
CCR7+/−CD39+CD103+ (DP). For TCR sequencing analysis, cell pellets were frozen
until further processing.
For expansion of DN, SP, and DP CD8 TILs as well as naive and memory CD8
from PBMC, T cells were sorted and cultured in complete RPMI-1640,
supplemented with 2 mM glutamine, 1% (vol/vol) nonessential amino acids, 1%
(vol/vol) sodium pyruvate, penicillin (50 U/ml), streptomycin (50 μg/ml), and 10%
fetal bovine serum (Hyclone). Of note, for functional assays and expansion, no
CD3 antibody was used for cell sorting. Sorted T cells were stimulated polyclonally
with 1 µg/ml Phytohemagglutinin (PHA) (Sigma) in the presence of irradiated
(4000 rad) allogeneic feeder cells (PBMC; 2 × 105 cells per well) and 10 ng/ml of
interleukin (IL)-15 (Biolegend) in a 96-well round-bottom plate (Corning/Costar).
T-cell lines were maintained in complete medium with IL-15 until analysis.
Microarray data acquisition. Samples for microarray were sorted as indicated
above. Sorted cells were lyzed and RNA was purified using Direct-zol RNA
MiniPrep kit (Zymo Research). RNA was then reverse transcribed to com-
plementary DNA (cDNA) and amplified. Amplified cDNA was hybridized on a
Affymetrix Prime-View gene chip.
Microarray data analysis. Image processing and expression analysis were per-
formed using Affymetrix GeneChip Command Console (AGCC) v.3.1.1 and
Affymetrix Expression Console v.1.1 software, respectively. Image processing of
sample DAT files to generate sample CEL files was completed in Affymetrix
Command Console software. Next, CEL were uploaded to Expression Console and
were normalized using the RMA normalization and summarization algorithm. To
determine differentially expressed genes between DP and DN CD8 TIL cells, we
used the Limma package45 lmFit to assess significance using half of the probes with
the greatest overall variance (24,361). p-values were adjusted using the
Benjamini–Hochberg method and probes with adjusted p-values <0.05 were con-
sidered significant. This resulted in 303 probes, mapping to 219 unique genes. A
heatmap was constructed using expression values for the unique genes normalized
to the mean across all cells. PCA was performed on the significantly differential
probes using the princomp function in the R statistical language (R Core Team
(2016). R: A language and environment for statistical computing. R Foundation for
Statistical Computing, Vienna, Austria).
The functional enrichment of DP vs. DN genes and DP vs. SP genes was
analyzed by ranking all genes based on fold-change difference in expression, then
applying GSEA46, to test enrichment of several previously published T-cell gene
signatures. The TRM signature was constructed from several studies47–49 as the
union set of up or downregulated genes from each. The false-discovery rate-
adjusted p-values are reported (q value), with q values <0.05 considered significant.
In vitro T-cell activation. Naive CD8 T-cell subsets were isolated by magnetic
CD8 T-cell enrichment (Stemcell), labeled with antibodies against CD4, CD8,
CD45RA, and CCR7, and sorted as indicated above. 1 × 105 naive T cells were
cultured with anti-CD3/CD28 Dynabeads (Life Technologies) at a bead:T-cell ratio
of 1:2 in the presence or absence of 2 ng/ml TGFβ-1 (R&D). After 24 h, beads were
removed by magnetic capture for half of the experiment. Expression of activation
and differentiation markers was assessed at days 1, 2, 3, 4, 7, and 9.
DNA preparation and TCRβ deep sequencing. Deep sequencing of the variable
V–J or V–D–J regions of TCRβ genes was performed on genomic DNA of sorted T-
cell populations. DNA was extracted from circulating and tumor-resident CD8 T-
cell subsets ranging from 1 × 104–1 × 105 cells (DNeasy Blood and Tissue Kit,
Qiagen). The TCRβ CDR3 regions were sequenced and mapped (ImmunoSEQ,
Adaptive Biotech). Coverage per sample was >10×. Only data from productive
rearrangements were extracted from the ImmunoSEQ Analyzer platform for fur-
ther analysis. Clonality of the different T-cell subsets was assessed by nucleotide
sequence comparison of the 500 most abundant clones in each subset.
To compare the TCR Vβ overlap (or similarity) of two given populations, we
used the Morisita’s overlap and the Jaccard index. The Morisita–Horn similarity
index accounts for both, the number of common clonotypes and the distribution of
clonotype sizes, and is most sensitive to the clone sizes of the dominant
clonotypes50. The Jaccard index accounts for the proportion of shared clonotypes
between samples.
Assessment of target cell recognition. Upregulation of 4-1BB as well as release of
IFN-γ were used as measures to assess recognition of tumor cells by expanded
autologous CD8 T cells. The co-culture experiment was performed 17–20 days after
expansion. Expanded CD8 T cells (1 × 105) were then cultured either alone or with
increasing numbers of autologous tumor cells (ranging from 781 to 100,000 cells per
well). In some conditions, tumor cells were pre-incubated with 50 μg/ml of anti-
MHC-class I blocking antibody (Biolegend, clone W6/32—#311428) for 1 h prior to
adding T cells. To confirm tumor reactivity, expanded CD8 T cells were cultured
with allogeneic tumor cells. As positive control, Nunc Maxisorp plates were coated
with 1 μg/ml anti-CD3 antibody (OKT3) and T cells were added. All conditions
were plated in triplicate. After 20 h, supernatants were harvested and analyzed by
enzyme-linked immunosorbent assay (ELISA). Cells were collected and labeled with
a viability dye, followed by CD39, CD103, CD25, and 4-1BB cell surface staining.
Cells were analyzed by flow cytometry. For the ELISA, the manufacturer’s protocol
(BD Biosciences) was followed and secretion of IFN-γ was analyzed.
Live target cell killing assay. T-cell-mediated target cell killing assays were per-
formed in the Incucyte Zoom System housed inside a cell incubator at 37 °C/5%
CO2, based on the manufacturer’s protocol (Essen Bioscience). To assess T-cell
killing of autologous tumor cells, 5000–10,000 tumor cells (autologous and allo-
geneic tumor cell lines) were seeded in triplicate into a 96-well flat-bottom plate to
reach 10% confluence. Expanded autologous T-cell subsets were counted and 1 ×
105 T cells were cultured with and without autologous and allogeneic tumor cells in
medium without exogenous IL-15 (T cell:tumor cell ratio of 10:1). In some wells,
anti-MHC-class I antibody (Biolegend, clone W6/32) was added. In all conditions,
NucView 488 Caspase 3/7 substrate (Essen Bioscience) was added to monitor
active caspase 3/7. Plates were incubated for 24 h at 37 °C and four images were
captured from three experimental replicates every hour using a ×10 objective lens
to visualize T-cell killing and caspase 3/7 activity (green fluorescence). Green
channel acquisition time was 400 ms. For phase contrast, cell segmentation was
achieved by applying a mask to exclude the smaller T cells. An area filter was
applied to exclude objects below 1000 μm2. Green background noise was subtracted
with the Top-Hat method of background non-uniformity correction with a radius
of 20 μm and a threshold of two green corrected units. Fluorescence signal was
quantified after applying the mask to the experiment. Amount of T-cell killing/
apoptosis was calculated by the Zoom software provided (Essen Bioscience).
IFN-γ Enzyme-Linked ImmunoSpot (ELISPOT) assay. Briefly, ELIIP plates
(Millipore, MAIPSWU10) were pretreated with 50 µl per well of 70% ethanol for 2
min, washed 3× with PBS, and then coated with 50 µl of 10 µg/ml IFN-γ capture
antibody (Mabtech, clone: 1-D1K), and incubated overnight in the fridge. For
OKT3 controls, wells were coated with a mixture of IFN-γ capture antibody (10 µg/
ml) and OKT3 (1 µg/ml). Prior to co-culture, the plates were washed 1× with PBS,
followed by blocking with complete RPMI media for at least 1 h at room tem-
perature. After 24 h of co-culture, the ELISPOT plates were washed 6× with PBS+
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0.05% Tween-20 (PBS-T), and then incubated for 2 h at room temperature with
100 µl per well of a 0.22 µm-filtered 1 µg/ml biotinylated anti-human IFN-γ
detection antibody solution (Mabtech, clone: 7-B6-1, diluent consisted of 1× PBS
supplemented with 0.5% FBS). The plate was then washed 3× with PBS-T, followed
by 1 h incubation with 100 µl per well of streptavidin-ALP (Mabtech, diluted
1:3000 with above diluent). The plate was washed 5× with PBS followed by
development with 100 µl per well of 0.45 µm-filtered BCIP/NBT substrate solution
(KPL, Inc.). The reaction was stopped by rinsing thoroughly with cold tap water.
ELISPOT plates were scanned and counted using an ImmunoSpot plate reader and
associated software (Cellular Technology Limited).
Survival data and analysis. For the OS analysis, the survival time was calculated
from the time of surgery until last contact or death. The censoring proportion of
survival data was 47 of 62 patients (for details, see Supplementary Table 5). The
frequency of DP CD8 T cells among total CD8 TILs in all 62 HNSCC tumors was
evaluated at time of surgery. We compared OS between DP low and DP high using
the mean frequency of DP CD8 TILs calculated from all 62 patients as a cut point
(mean= 32.9%). This cut point was not only clinically important but also best
discriminate patient survival, as confirmed using the score (or log-rank) statistics in
the R function cutp() from the package “survMisc” (Chris Dardis (2016). survMisc:
Miscellaneous Functions for Survival Data. R package version 0.5.4; https://cran.r-
project.org/web/packages/survMisc/index.html). Patient characteristics between
groups were evaluated using Fisher exact tests for categorical, and t test or non-
parametric Kruskal–Wallis rank sum tests for continuous variables. Univariate
survival analysis was performed using the Kaplan–Meier method and p-values were
determined using log-rank test. Multivariable survival analysis was performed
using Cox-proportional model with Firth’s penalized likelihood (Heinze and
Ploner (2016). coxphf: Cox regression with Firth’s penalized likelihood. R package
version 1.12; https://CRAN.R-project.org/package=coxphf), which has been shown
as a good alternative to Cox’s regression model with a more precise estimation of
parameters for small samples with substantial censoring of survival times51. It
produces finite parameter estimates using penalized maximum likelihood estima-
tion for monotone likelihood that primarily occurs in small samples with high
percentage of censoring observed in a Cox model. Therefore, we adopted this
penalization approach for the multivariable survival analysis in this study. In order
to fully capture the effect of DP CD8 on OS, we also performed the survival
analysis taking DP CD8 as continuous variable with log(2) transformed without
dichotomizing them. All statistical tests were two-sided tests. The statistical ana-
lyses were performed using R statistical software, version 3.3.2.
Survival data and analysis TCGA. The data used was downloaded from the
TCGA repository. All available mRNA expression data was downloaded from the
following projects: TCGA-HNSC (head and neck squamous cell carcinoma),
TCGA-LUAD (lung adenocarcinoma), and TCGA-LUSC (lung squamous cell
carcinoma). The clinical data for the same projects was downloaded in R using the
RTCGA package. We analyzed patient survival according to the expression of the
transcripts for ENTPD1 (CD39) and ITGAE (CD103). To determine the ideal point
to divide groups, the R package ‘survminer’ was used. The surv_cutpoint() func-
tion, which uses the maximally selected rank statistics from the ‘maxstat’ R
package, was used to split each of the genes into high- or low-expresser groups.
Following this analysis, the CD39hiCD103hi and CD39loCD103lo groups were
established and isolated. The survival and ggplot2 R packages were used to create
Kaplan–Meier plots for each of the selected types of cancer including p-values
determined by log-rank test.
Statistical analysis. Statistical significance between groups was determined by
one-way analysis of variance analysis with Tukey correction, using GraphPad
Prism 6 software (GraphPad, San Diego, CA).
Data availability. All data are available from the corresponding authors upon
reasonable request. Gene-expression raw data that support the findings of this
study have been deposited in Gene Expression Omnibus under the accession
number GSE114944. TCR sequencing data have been deposited in the Immu-
neACCESS database under the accession code DOI:10.21417/B7ZW6H (http://
clients.adaptivebiotech.com/pub/Duhen-2018-natcomms).
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